中文版Tasly Biopharmaceuticals Co. Ltd. 
YU Yongsheng
Strategic Investment Mgr.Tasly Biopharmaceuticals Co., Ltd.
Tasly Biopharma with its headquarter in Shanghai focuses on the development of biologic drugs in the therapeutic areas of cardiovascular diseases, oncology and autoimmune, and alimentary tract and metabolism. Our target therapeutic areas are among the largest and fastest growing therapeutic areas in China, where biologics are expected to become one of the key growth drivers.
Pro-UK is an innovative biologics drug manufactured and commercialized by Tasly Biopharma, which is indicated for STEMI thrombolysis with a better efficacy and safety profile than alteplas. In addition to Pro-UK, we have a rich biopharmaceutical products under development.
Tasly has collaborated with various overseas companies, including Transgene, Pharnext, EA, Eli Lilly, APbio, etc.. Some of the assets from collaboration have been successfully transferred to China, and clinical trials have been initiated.
Tasly is actively looking for partnerships on clinical-stage to marketed assets, through straight licensing, co-development, strategic investment, etc. in the abovementioned disease areas to bring the asset to China market.
Miss Eugenia Yu
BD directorTF Capital
Alex Li
Managing DirectorMr. Allan Liu
Vice PresidentTopwin pharma
Miss Ocean Chen
BDMTOT BIOPHARM
About TOT BIOPHARM International Company Limited
(HKG:1875)
TOT BIOPHARM is dedicated to developing and commercializing innovative cancer drugs and therapies, striving to build a leading brand of oncology treatments trusted by patients and their families as well as medical professionals.
The Group has in place three major integrated technology platforms:
Therapeutic Monoclonal Antibody and Antibody Drug Conjugates (ADCs) Technology Platform: it integrates research and development (R&D) and production capacities for antibody drugs and ADCs, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates;
Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumor immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumor-targeted oncolytic virus products;
Innovative Drug Delivery Technology Platform: We have developed an innovative drug delivery system, including an advanced targeted liposome drug delivery system.
Using these platforms, the Group has studied and developed various anti-tumor drug series, and formed a high quality and comprehensive drug product chain. Currently, the Group has 12 drugs under research and development. On top of developing innovative proprietary drugs, TOT BIOPHARM also draws on its own industry value chain to build a complete industry chain platform that supports from R&D, clinical development to production and marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties in different stages along its industry value chain.
Lily Lien
DirectorTrinity Innovation Bioventure Fund
Na Wen
PartnerUsurpo Ltd. 
We work closely with Pharmaceutical, Biotechnology, Medical Device companies and service providers to help them build exceptional leadership teams, particularly across Europe and the US. We have a track record of helping international business from China, Japan, Israel and Korea make key hires in the US and Europe for their expanding international teams.
We help our clients to hire Senior Director, VP and C-suite level professionals into the following areas:
- Clinical Development (Chief Medical Officer, Chief Development Officer, Medical Director, Therapeutic area experts)
- Regulatory Affairs
- CMC
- Business Development (Licensing, M&A, Corporate Development)
- Business Development (Sales and business expansion for service providers)
- Cross functional C-suite leadership
- Sales and Marketing leaders
Mr. Christopher Gibson
Head of Practice, Life SciencesViva Bioinnovator
Dr Cynthia Cai
Venture Partner
Mrs. qianyi zhao
Senior Associate
WolwoPharma
and the largest allergen preparation supplier in Asia.
Responsive Web Design powered by 